Downloadable summary slides with quick expert analysis of the optimal management of patients with HER2-positive metastatic breast cancer, from Clinical Care Options.
Read this commentary from Clinical Care Options to gain expert perspectives on PARP inhibition in early, metastatic, and triple-negative breast cancer.
On-demand Webcast featuring expert discussion of new therapies for relapsed/refractory HER2-positive metastatic breast cancer, from a live CCO Webinar
Expert commentary from Cristina Saura, MD, PhD, with answers to frequently asked questions on managing HER2-positive metastatic breast cancer from CCO
For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.